[July 28, 2015]

Research and Markets: Lung Transplantation Therapeutics Pipeline Review, H1 2015 - 3 Companies & 7 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/nfxsfc/lung) has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Lung Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also revews key players involved in the therapeutic development for Lung Transplantation and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Kamada Ltd.
• Proteo, Inc.
• Quark Pharmaceuticals, Inc.

Drug Profiles

• alpha-1 proteinase inhibitor (human)
• Elafin
• FX-06
• R-503
• R-801
• Recombinant Human Follistatin
• RNAi Oligonucleotide for Lung Diseases

For more information visit http://www.researchandmarkets.com/research/nfxsfc/lung

View source version on businesswire.com: http://www.businesswire.com/news/home/20150728006041/en/

[ Back To TMCnet.com's Homepage ]